Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer (ARC-7)

August 25, 2025 updated by: Arcus Biosciences, Inc.

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This is an open-label phase 2 study in participants with non-small cell lung cancer which will assess the safety, efficacy and tolerability of zimberelimab as monotherapy and in combination with other immunotherapeutics across multiple treatment arms.

Approximately 150 participants will be randomized to 1 of 3 treatment arms: 1) zimberelimab, 2) zimberelimab + domvanalimab (anti-TIGIT antibody), 3) zimberelimab + domvanalimab + etrumadenant (dual adenosine receptor antagonist). Participants that progress on the zimberelimab monotherapy arm may cross-over to receive the third arm combination of zimberelimab + domvanalimab + etrumadenant.

The primary objective of this clinical study is to evaluate the efficacy of each combination therapy by assessing: 1) objective response rate (ORR) of participants with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) and 2) progression free survival (PFS).

Study Type

Interventional

Enrollment (Actual)

151

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Albury, Australia
        • Border Medical Oncology
      • Coffs Harbour, Australia
        • Coffs Harbour Health Campus
      • Elizabeth Vale, Australia
        • Adelaide Cancer Centre
      • Nowra, Australia
        • Shoalhaven Cancer Care Centre
  • Canada
      • Montreal, Canada
        • McGill University Health Centre (MUHC) - The Montreal Children's Hospital (MCH)
  • Hong Kong
      • Hong Kong, Hong Kong
        • Hong Kong United Oncology Centre
      • Hong Kong, Hong Kong
        • Queen Elizabeth Hospital (Hong Kong)
  • Singapore
      • Singapore, Singapore
        • Curie Oncology
  • South Korea
      • Busan, South Korea
        • Kosin University Gospel Hospital
      • Cheongju-si, South Korea
        • Chungbuk National University Hospital (CBNUH)
      • Hwasun, South Korea
        • Chonnam University Hospital
      • Incheon, South Korea
        • Gachon University Gil Medical Center
      • Jeonju, South Korea
        • Chonbuk National University Hospital
      • Seongnam-si, South Korea
        • Seoul National University Bundang Hospital
      • Seoul, South Korea
        • Asan Medical Center
      • Seoul, South Korea
        • Kangbuk Samsung Hospital
      • Seoul, South Korea
        • Korea University Anam Hospital
      • Suwon, South Korea
        • St Vincent Hospital of the Catholic University of Korea
      • Uijeongbu-si, South Korea
        • Catholic University of Korea, Uijeongbu St. Mary's Hospital
  • Taiwan
      • New Taipei City, Taiwan
        • Taipei Medical University - Shuang Ho Hospital
      • Tainan City, Taiwan
        • National Cheng Kung University Hospital
      • Tainan City, Taiwan
        • Chi Mei Hospital
      • Taipei, Taiwan
        • National Taiwan University Hospital
      • Taipei, Taiwan
        • Taipei Medical University Hospital
      • Taoyuan District, Taiwan
        • Chang Gung Memorial Hospital at Linkou
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
        • University of Alabama at Birmingham
    • California
      • Whittier, California, United States, 90603
        • Innovative Clinical Research Institute (ICRI)
    • Florida
      • Englewood, Florida, United States, 34223
        • Florida Cancer Specialists
      • Gainesville, Florida, United States, 32605
        • Florida Cancer Specialists
      • Tallahassee, Florida, United States, 32308
        • Florida Cancer Specialists - Panhandle
      • West Palm Beach, Florida, United States, 33401
        • Florida Cancer Specialists - East
    • Kentucky
      • Lexington, Kentucky, United States, 40503
        • Baptist Health Lexington
      • Louisville, Kentucky, United States, 40202
        • Norton Cancer Institute
    • Louisiana
      • New Orleans, Louisiana, United States, 70121
        • Ochsner Clinic Foundation
    • New Jersey
      • Ridgewood, New Jersey, United States, 07450
        • The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion
    • New York
      • Lake Success, New York, United States, 11042
        • Clinical Research Alliance
      • Lake Success, New York, United States, 11042
        • Northwell Health Cancer Institute
    • North Carolina
      • Winston-Salem, North Carolina, United States, 27157
        • Wake Forest Baptist Health
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15224
        • Allegheny General Hospital (AGH)-Alleghney Singer Research Institute
    • Tennessee
      • Nashville, Tennessee, United States, 37203
        • Sarah Cannon Research Institute
    • Texas
      • Fort Worth, Texas, United States, 76104
        • The Center For Cancer And Blood Disorders (Texas Cancer Care)
      • Houston, Texas, United States, 77339
        • Millennium Oncology
    • Virginia
      • Blacksburg, Virginia, United States, 24060
        • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
      • Fairfax, Virginia, United States, 22031
        • Virginia Cancer Specialists

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female participants; age ≥ 18 years
  • Histologically confirmed, treatment naive, metastatic squamous or non-squamous NSCLC with documented high PD-L1 expression, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
  • Must have at least 1 measurable lesion per RECIST v1.1
  • Adequate organ and marrow function

Exclusion Criteria:

  • Use of any live vaccines against infectious diseases within 28 days of first dose of investigational medicinal products (IMPs)
  • Any gastrointestinal condition that would preclude the use of oral medications (eg, difficulty swallowing, nausea, vomiting, or malabsorption)
  • History of trauma or major surgery within 28 days prior to the first dose of IMP
  • Concurrent medical condition requiring the use of supra-physiologic doses of corticosteroids (> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications
  • Positive test results for Hepatitis B surface antigen, Hepatitis C virus antibody with presence of Hepatitis C qualitative RNA or human immunodeficiency virus (HIV-1 and/or HIV-2) antibody at screening
  • Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy.
  • Prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or prostate cancer

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Arm 1 (zimberelimab monotherapy)
Participants will receive zimberelimab as an intravenous (IV) infusion.
Drug: Zimberelimab
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Other Names:
  • AB122
Experimental: Arm 2 (domvanalimab and zimberelimab combination therapy)
Participants will receive domvanalimab IV in combination with zimberelimab IV infusion.
Drug: Zimberelimab
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Other Names:
  • AB122
Drug: Domvanalimab
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Other Names:
  • AB154
Experimental: Arm 3 (domvanalimab, etrumadenant, and zimberelimab combination therapy)
Participants will receive oral etrumadenant in combination with domvanalimab IV and zimberelimab IV infusion
Drug: Etrumadenant
Etrumadenant is an A2aR and A2bR antagonist
Other Names:
  • AB928
Drug: Zimberelimab
Zimberelimab is a fully human anti-PD-1 monoclonal antibody
Other Names:
  • AB122
Drug: Domvanalimab
Domvanalimab is a humanized monoclonal antibody targeting human TIGIT
Other Names:
  • AB154

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective response rate (ORR)
Time Frame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
ORR as assessed by RECIST v1.1
From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
Progression-free survival (PFS)
Time Frame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
PFS as assessed by RECIST v1.1
From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of response (DoR)
Time Frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
DoR as assessed by RECIST v1.1
From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
Overall Survival (OS)
Time Frame: From randomization to death from any cause (up to approximately 5 years)
OS as assessed at the time of PFS
From randomization to death from any cause (up to approximately 5 years)
Pharmacokinetics of zimberelimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
Serum concentration of zimberelimab as determined by validated assays
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
Pharmacokinetics of domvanalimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
Serum concentration of domvanalimab as determined by validated assays
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
Pharmacokinetics of etrumadenant
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
Serum concentration of etrumadenant as determined by validated assays
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, 60 and 100 days post last dose (in total, an average of 2 years)
Immunogenicity of zimberelimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
Percentage of participants who develop treatment-emergent anti-drug antibodies to zimberelimab
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
Immunogenicity of domvanalimab
Time Frame: Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
Percentage of participants who develop treatment-emergent anti-drug antibodies to domvanalimab
Collected during all treatment cycles (each cycle is 21 or 28 days), up to 14 days post last dose, 30, and 100 days post last dose (in total, an average of 2 years).
Disease control rate (DCR)
Time Frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
DCR as assessed by RECIST v1.1
From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
Number of Participants with Treatment Emergent Adverse Events (TEAEs)
Time Frame: From Screening until up to 90-100 days after the last dose (approximately 5 years)
The number and percentage of participants that experience TEAE
From Screening until up to 90-100 days after the last dose (approximately 5 years)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Arcus Biosciences, Inc.

Collaborators

Gilead Sciences

Investigators

  • Study Director: Medical Director, Arcus Biosciences, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 28, 2020

Primary Completion (Actual)

June 5, 2025

Study Completion (Actual)

July 9, 2025

Study Registration Dates

First Submitted

January 23, 2020

First Submitted That Met QC Criteria

February 7, 2020

First Posted (Actual)

February 10, 2020

Study Record Updates

Last Update Posted (Estimated)

August 26, 2025

Last Update Submitted That Met QC Criteria

August 25, 2025

Last Verified

August 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ARC-7 (AB154CSP0002)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.

For more information, please visit our website.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • CSR

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Lung Cancer

Clinical Trials on Etrumadenant

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Lebanon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe